Therapeutic benefit of radiotherapy in huge (≥10 cm) unresectable hepatocellular carcinoma

Kyung Hwan Kim, Mi Sun Kim, Jee Suk Chang, KwangHyub Han, doyoung kim, Jinsil Seong

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background & Aims: Huge (≥10 cm) hepatocellular carcinomas (HCCs) show dismal prognosis and only a limited number of cases are eligible for curative resection. We studied the therapeutic benefit of radiotherapy (RT) in patients with huge unresectable HCCs. Methods: Data from 283 patients with huge HCCs and preserved liver function who underwent non-surgical treatment from July 2001 to March 2012 were retrospectively reviewed. Patients were divided into 4 groups according to the initial treatment: Group A (N= 49), transarterial chemoembolization (TACE); Group B (N = 35), TACE + RT; Group C (N = 50), hepatic arterial infusion chemotherapy; and Group D (n = 149), concurrent chemoradiotherapy (CCRT). Results and Conclusions: The median follow-up period was 27.8 months (range, 12.9-121.9 months). The median overall survival (OS) was longer in Groups B (15.3 months) and D (12.8 months) than in Groups A (7.5 months) and C (8.2 months; Group B vs. A, Bonferroni corrected P [P c ] = 0.04; Group B vs. C, P c = 0.02; Group D vs. A, P c = 0.01; Group D vs. C, P c = 0.006). Groups B and D also showed superior progression-free survival (PFS) and intrahepatic control than Groups A and C. In multivariate analysis, tumour multiplicity, serum alpha-foetoprotein level (≥200 ng/ml) and initial treatment were independent prognostic factors for OS and PFS. Patients with huge unresectable HCCs treated with RT, either as CCRT or in combination with TACE, showed excellent intrahepatic control and prolonged survival. RT could be considered a promising treatment modality in these patients.

Original languageEnglish
Pages (from-to)784-794
Number of pages11
JournalLiver International
Volume34
Issue number5
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Hepatocellular Carcinoma
Radiotherapy
Chemoradiotherapy
Disease-Free Survival
Survival
Therapeutics
Liver
alpha-Fetoproteins
Multivariate Analysis
Drug Therapy
Control Groups
Serum
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

@article{80d2c45f0c084838aa7f7de267cfd06c,
title = "Therapeutic benefit of radiotherapy in huge (≥10 cm) unresectable hepatocellular carcinoma",
abstract = "Background & Aims: Huge (≥10 cm) hepatocellular carcinomas (HCCs) show dismal prognosis and only a limited number of cases are eligible for curative resection. We studied the therapeutic benefit of radiotherapy (RT) in patients with huge unresectable HCCs. Methods: Data from 283 patients with huge HCCs and preserved liver function who underwent non-surgical treatment from July 2001 to March 2012 were retrospectively reviewed. Patients were divided into 4 groups according to the initial treatment: Group A (N= 49), transarterial chemoembolization (TACE); Group B (N = 35), TACE + RT; Group C (N = 50), hepatic arterial infusion chemotherapy; and Group D (n = 149), concurrent chemoradiotherapy (CCRT). Results and Conclusions: The median follow-up period was 27.8 months (range, 12.9-121.9 months). The median overall survival (OS) was longer in Groups B (15.3 months) and D (12.8 months) than in Groups A (7.5 months) and C (8.2 months; Group B vs. A, Bonferroni corrected P [P c ] = 0.04; Group B vs. C, P c = 0.02; Group D vs. A, P c = 0.01; Group D vs. C, P c = 0.006). Groups B and D also showed superior progression-free survival (PFS) and intrahepatic control than Groups A and C. In multivariate analysis, tumour multiplicity, serum alpha-foetoprotein level (≥200 ng/ml) and initial treatment were independent prognostic factors for OS and PFS. Patients with huge unresectable HCCs treated with RT, either as CCRT or in combination with TACE, showed excellent intrahepatic control and prolonged survival. RT could be considered a promising treatment modality in these patients.",
author = "Kim, {Kyung Hwan} and Kim, {Mi Sun} and Chang, {Jee Suk} and KwangHyub Han and doyoung kim and Jinsil Seong",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/liv.12436",
language = "English",
volume = "34",
pages = "784--794",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "5",

}

Therapeutic benefit of radiotherapy in huge (≥10 cm) unresectable hepatocellular carcinoma. / Kim, Kyung Hwan; Kim, Mi Sun; Chang, Jee Suk; Han, KwangHyub; kim, doyoung; Seong, Jinsil.

In: Liver International, Vol. 34, No. 5, 01.01.2014, p. 784-794.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Therapeutic benefit of radiotherapy in huge (≥10 cm) unresectable hepatocellular carcinoma

AU - Kim, Kyung Hwan

AU - Kim, Mi Sun

AU - Chang, Jee Suk

AU - Han, KwangHyub

AU - kim, doyoung

AU - Seong, Jinsil

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background & Aims: Huge (≥10 cm) hepatocellular carcinomas (HCCs) show dismal prognosis and only a limited number of cases are eligible for curative resection. We studied the therapeutic benefit of radiotherapy (RT) in patients with huge unresectable HCCs. Methods: Data from 283 patients with huge HCCs and preserved liver function who underwent non-surgical treatment from July 2001 to March 2012 were retrospectively reviewed. Patients were divided into 4 groups according to the initial treatment: Group A (N= 49), transarterial chemoembolization (TACE); Group B (N = 35), TACE + RT; Group C (N = 50), hepatic arterial infusion chemotherapy; and Group D (n = 149), concurrent chemoradiotherapy (CCRT). Results and Conclusions: The median follow-up period was 27.8 months (range, 12.9-121.9 months). The median overall survival (OS) was longer in Groups B (15.3 months) and D (12.8 months) than in Groups A (7.5 months) and C (8.2 months; Group B vs. A, Bonferroni corrected P [P c ] = 0.04; Group B vs. C, P c = 0.02; Group D vs. A, P c = 0.01; Group D vs. C, P c = 0.006). Groups B and D also showed superior progression-free survival (PFS) and intrahepatic control than Groups A and C. In multivariate analysis, tumour multiplicity, serum alpha-foetoprotein level (≥200 ng/ml) and initial treatment were independent prognostic factors for OS and PFS. Patients with huge unresectable HCCs treated with RT, either as CCRT or in combination with TACE, showed excellent intrahepatic control and prolonged survival. RT could be considered a promising treatment modality in these patients.

AB - Background & Aims: Huge (≥10 cm) hepatocellular carcinomas (HCCs) show dismal prognosis and only a limited number of cases are eligible for curative resection. We studied the therapeutic benefit of radiotherapy (RT) in patients with huge unresectable HCCs. Methods: Data from 283 patients with huge HCCs and preserved liver function who underwent non-surgical treatment from July 2001 to March 2012 were retrospectively reviewed. Patients were divided into 4 groups according to the initial treatment: Group A (N= 49), transarterial chemoembolization (TACE); Group B (N = 35), TACE + RT; Group C (N = 50), hepatic arterial infusion chemotherapy; and Group D (n = 149), concurrent chemoradiotherapy (CCRT). Results and Conclusions: The median follow-up period was 27.8 months (range, 12.9-121.9 months). The median overall survival (OS) was longer in Groups B (15.3 months) and D (12.8 months) than in Groups A (7.5 months) and C (8.2 months; Group B vs. A, Bonferroni corrected P [P c ] = 0.04; Group B vs. C, P c = 0.02; Group D vs. A, P c = 0.01; Group D vs. C, P c = 0.006). Groups B and D also showed superior progression-free survival (PFS) and intrahepatic control than Groups A and C. In multivariate analysis, tumour multiplicity, serum alpha-foetoprotein level (≥200 ng/ml) and initial treatment were independent prognostic factors for OS and PFS. Patients with huge unresectable HCCs treated with RT, either as CCRT or in combination with TACE, showed excellent intrahepatic control and prolonged survival. RT could be considered a promising treatment modality in these patients.

UR - http://www.scopus.com/inward/record.url?scp=84897959514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897959514&partnerID=8YFLogxK

U2 - 10.1111/liv.12436

DO - 10.1111/liv.12436

M3 - Article

VL - 34

SP - 784

EP - 794

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 5

ER -